Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 38-year-old man is evaluated in the hospital on day 4 of admission for an acute left lower extremity deep vein thrombosis. He has a known history of primary antiphospholipid syndrome. Upon admission, he was started on a continuous intravenous unfractionated heparin infusion and oral warfarin.

Daily INR values since admission are as follows:

Hospital DayINR Result
Day 11.1
Day 21.2
Day 31.7
Day 4 (today)2.4

Today's laboratory results show an activated partial thromboplastin time (aPTT) of 68 seconds (therapeutic goal: 60-80 seconds). His platelet count is 210,000/mm³ (baseline 225,000/mm³ on admission). The patient reports that his leg swelling has significantly improved, though he still experiences mild residual leg pain. He has no signs of clinical bleeding.

Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. A
    Discontinue warfarin and transition to oral rivaroxaban
  2. B
    Discontinue the unfractionated heparin infusion and continue oral warfarin
  3. Continue both the unfractionated heparin infusion and oral warfarinCevap
  4. D
    Hold the next dose of warfarin and continue the unfractionated heparin infusion
  5. E
    Prescribe oral naproxen for the residual leg pain and continue the current anticoagulants

Cevap

Continue both the unfractionated heparin infusion and oral warfarin
The most appropriate next step in management is to continue both the unfractionated heparin infusion and oral warfarin. When initiating a vitamin K antagonist (warfarin) for the treatment of an acute deep vein thrombosis, patients must receive concurrent bridging therapy with a rapid-acting parenteral anticoagulant. This overlap must be maintained for a strict minimum of 5 days AND until the INR is in the therapeutic range (typically 2.0-3.0) for at least 24 hours. Because the patient is only on day 4 of admission and his INR just entered the therapeutic range today (it was 1.7 yesterday), neither of the required safety thresholds has been fulfilled. Therefore, both medications must be continued to prevent a transient hypercoagulable state.

Adım Adım Çözüm

1
Evaluate the current duration of the parenteral and oral anticoagulant overlap.
The patient has been on combined unfractionated heparin and warfarin therapy for exactly 4 days.
Current standard-of-care guidelines mandate a minimum of 5 days of overlap for safe warfarin initiation.
2
Analyze the patient's current INR in the context of therapeutic goals and timeline requirements.
The INR reached the therapeutic range (2.4) for the first time today; yesterday it was subtherapeutic (1.7).
Heparin can only be discontinued safely when the INR has been therapeutic (2.0 or greater) for a minimum of 24 consecutive hours.
3
Synthesize the duration and laboratory parameters to determine the immediate management step.
Unfractionated heparin must be continued concurrently with warfarin.
Neither the minimum 5-day duration rule nor the 24-hour therapeutic INR requirement has been satisfied.

Anahtar Kavram

For the treatment of venous thromboembolism, bridging therapy with a parenteral anticoagulant (such as unfractionated heparin) and warfarin must be continued concurrently for a minimum of 5 days AND until the INR is therapeutic (2.0 or greater) for at least 24 hours.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru